Galera Therapeutics

galeratx.com

Stage

IPO

Total Raised

$142.94M

Investors Count

Deal Terms

Portfolio Exits

Investments

Funding, Valuation & Revenue

13 Fundings

Galera Therapeutics has raised $142.94M over 13 rounds.

Galera Therapeutics's latest funding round was a Bankrupt/Admin for on August 14, 2024.

Galera Therapeutics's valuation in November 2019 was $292.34M.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
8/14/2024	Bankrupt/Admin			$XXM	0 FY undefined	2
11/7/2019	IPO	$60M	Public	$292.34M	0 FY undefined	3
8/30/2018	Series C	$70M	Adage Capital Management, Clarus, Correlation Ventures, Galera Angels, HBM Healthcare Investments, NEA, Nan Fung, Novartis Venture Funds, Novo Ventures, RA Capital Management, Rock Springs Capital, Sofinnova Ventures, and abrdn	$XXM	0 FY undefined	4
11/28/2016	Series B - III	$XXM	Subscribe to see more	$XXM	0 FY undefined	10
2/3/2016	Series B - II	$XXM	Subscribe to see more	$XXM	0 FY undefined	10

Date	8/14/2024	11/7/2019	8/30/2018	11/28/2016	2/3/2016
Round	Bankrupt/Admin	IPO	Series C	Series B - III	Series B - II
Amount		$60M	$70M	$XXM	$XXM
Investors		Public	Adage Capital Management, Clarus, Correlation Ventures, Galera Angels, HBM Healthcare Investments, NEA, Nan Fung, Novartis Venture Funds, Novo Ventures, RA Capital Management, Rock Springs Capital, Sofinnova Ventures, and abrdn	Subscribe to see more	Subscribe to see more
Valuation	$XXM	$292.34M	$XXM	$XXM	$XXM
Revenue	0 FY undefined	0 FY undefined	0 FY undefined	0 FY undefined	0 FY undefined
Sources	2	3	4	10	10

Galera Therapeutics Deal Terms

3 Deal Terms

Galera Therapeutics's deal structure is available for 3 funding rounds, including their IPO from November 07, 2019.

Round	IPO	Series B	Series A
Funding Date	$XXM	$XXM	$XXM
Pre-Money Valuation	$XXM
Post-Money Valuation	$XXM
Amount Raised	$XXM	$XXM	$XXM
Shares Authorized
Issuance Price			$XXM
Dividend Rate			$XXM
Liquidation Preferences			$XXM
Liquidation Price
Participation
Conversion Price
Anti Dilution			$XXM
General Voting	$XXM	$XXM	$XXM
Board Voting	$XXM	$XXM	$XXM
Par Value

Round	Funding Date	Pre-Money Valuation	Post-Money Valuation	Amount Raised	Shares Authorized	Issuance Price	Dividend Rate	Liquidation Preferences	Liquidation Price	Participation	Conversion Price	Anti Dilution	General Voting	Board Voting	Par Value
IPO	$XXM	$XXM	$XXM	$XXM									$XXM	$XXM
Series B	$XXM			$XXM									$XXM	$XXM
Series A	$XXM			$XXM		$XXM	$XXM	$XXM				$XXM	$XXM	$XXM

Galera Therapeutics Investors

18 Investors

Galera Therapeutics has 18 investors. Novartis Venture Funds invested in Galera Therapeutics's Series C funding round.

First funding	Last Funding	Investor	Rounds	Board Seats	Type	Location
12/10/2012	8/30/2018	Novartis Venture Funds	4 Series A, Series A - II (2014), Series B (2015), Series C (2018)		Corporate Venture	Switzerland
12/10/2012	8/30/2018	NEA	4 Series A, Series A - II (2014), Series B (2015), Series C (2018)	James Barrett	Venture Capital	California
12/10/2012	8/30/2018	Correlation Ventures	3 Series A, Series B (2015), Series C (2018)		Venture Capital	California
00/00/0000	00/00/0000	Novo Ventures	Subscribe to see more		Corporate Venture	California
00/00/0000	00/00/0000	Sofinnova Ventures	Subscribe to see more		Venture Capital	California

First funding	12/10/2012	12/10/2012	12/10/2012	00/00/0000	00/00/0000
Last Funding	8/30/2018	8/30/2018	8/30/2018	00/00/0000	00/00/0000
Investor	Novartis Venture Funds	NEA	Correlation Ventures	Novo Ventures	Sofinnova Ventures
Rounds	4 Series A, Series A - II (2014), Series B (2015), Series C (2018)	4 Series A, Series A - II (2014), Series B (2015), Series C (2018)	3 Series A, Series B (2015), Series C (2018)	Subscribe to see more	Subscribe to see more
Board Seats		James Barrett
Type	Corporate Venture	Venture Capital	Venture Capital	Corporate Venture	Venture Capital
Location	Switzerland	California	California	California	California

Galera Therapeutics Acquisitions

1 Acquisition

Galera Therapeutics acquired 1 company. Their latest acquisition was Nova Pharmaceuticals on December 31, 2024.

Date	Investment Stage	Companies	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Total Funding	Note	Sources
12/31/2024		Nova Pharmaceuticals	$XXM		Acquired	3

Date	12/31/2024
Investment Stage
Companies	Nova Pharmaceuticals
Valuation	$XXM
Total Funding
Note	Acquired
Sources	3

Galera Therapeutics Investments

3 Investments

Galera Therapeutics has made 3 investments. Their latest investment was in Galera Therapeutics as part of their Series B on October 14, 2015.

Galera Therapeutics Investments Activity

Date	Round	Company	Amount	New?	Co-Investors	Sources
10/14/2015	Series B	Galera Therapeutics	$37M	No	Correlation Ventures, NEA, Novartis Venture Funds, and Novo Ventures	2
6/15/2010	Seed	Subscribe to see more		Subscribe to see more	Subscribe to see more	0
	Other Investors	Subscribe to see more		Subscribe to see more		0

Date	10/14/2015	6/15/2010
Round	Series B	Seed	Other Investors
Company	Galera Therapeutics	Subscribe to see more	Subscribe to see more
Amount	$37M
New?	No	Subscribe to see more	Subscribe to see more
Co-Investors	Correlation Ventures, NEA, Novartis Venture Funds, and Novo Ventures	Subscribe to see more
Sources	2	0	0

Galera Therapeutics Portfolio Exits

1 Portfolio Exit

Galera Therapeutics has 1 portfolio exit. Their latest portfolio exit was Galera Therapeutics on November 07, 2019.

Date	Exit	Companies	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Acquirer	Sources
11/7/2019	IPO	Galera Therapeutics	$XXM	Public	3

Date	11/7/2019
Exit	IPO
Companies	Galera Therapeutics
Valuation	$XXM
Acquirer	Public
Sources	3

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.

How VCs Use CB Insights

Professional Services

Platform Overview